trending Market Intelligence /marketintelligence/en/news-insights/trending/cw5bn28ivcugabfqlsdw-a2 content esgSubNav
In This List

Strata Oncology secures $26M via equity financing

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Strata Oncology secures $26M via equity financing

Ann Arbor, Mich.-based Strata Oncology Inc. raised $26 million in a series B funding round.

The financing round included new investors Pfizer Inc., Merck & Co. Inc., Deerfield Management Co. LP and Renaissance Venture Capital Fund, along with existing investors Arboretum Ventures LLC and Baird Capital Partners.

Strata Oncology will use the proceeds to expand Strata Precision Oncology Network, a group of health systems using the company's platform to systematize tumor molecular profiling and precision therapy trials, and to further advance its clinical-genomic data and software solutions.

A portion of the proceeds is allocated to seek the U.S. Food and Drug Administration's approval for StrataNGS, the company's tumor molecular profiling assay, as well as to launch the company's pan-cancer molecular analysis for cancer therapy study.

Strata Oncology is a precision oncology company.